The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | TCTP: a potential biomarker and therapeutic target in gastric cancer
Hyung-Don Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, asserts the need for precise biomarkers for predicting immunotherapy response. Translationally controlled tumor protein (TCTP) may help address this, providing a more reliable way to stratify patients based on survival outcomes. Ongoing efforts are focused on developing therapeutics targeting TCTP to enhance treatment effectiveness. Given the finding of the study, TCTP-targeted approaches could hold significant potential for improving survival outcomes in gastric cancer patients. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
